A LC-MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma

被引:13
|
作者
Iacuzzi, Valentina [1 ]
Zanchetta, Martina [1 ,2 ]
Gagno, Sara [1 ]
Poetto, Ariana Soledad [1 ,3 ]
Orleni, Marco [1 ]
Marangon, Elena [1 ]
Guardascione, Michela [1 ]
Foltran, Luisa [4 ]
Posocco, Bianca [1 ]
Toffoli, Giuseppe [1 ]
机构
[1] Ctr Riferimento Oncol Aviano CRO IRCCS, Expt & Clin Pharmacol Unit, Via F Gallini 2, I-33081 Aviano, Italy
[2] Univ Trieste, Dept Chem & Pharmaceut Sci, Via Licio Giorgieri 1, I-34127 Trieste, Italy
[3] Univ Padua, Doctoral Sch Pharmacol Sci, Lgo Meneghetti 2, I-35131 Padua, Italy
[4] Ctr Riferimento Oncol Aviano CRO IRCCS, Dept Med Oncol, Via F Gallini 2, I-33081 Aviano, Italy
关键词
LC-MS/MS; Sorafenib; Regorafenib; Therapeutic drug monitoring; Hepatocellular carcinoma; TYROSINE KINASE INHIBITORS; HUMAN PLASMA; ASSAY;
D O I
10.1016/j.jpba.2020.113358
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the simultaneous quantification of sorafenib (SORA), its N-oxide active metabolite and of regorafenib (REGO) and its two active metabolites regorafenib N-oxide and N-desmethyl regorafenib N-oxide in hepatocellular carcinoma patients' plasma. A proper analytes' separation was obtained with Synergi Fusion RP column (4 mu m, 80 angstrom, 50 x 2.0 mm) using a gradient elution of 10 mM ammonium acetate with 0.1% formic acid (mobile phase A) and methanol:isopropanol (90:10, v/v, mobile phase B) containing 0.1% formic acid. The analysis was then performed by electrospray ionization in negative mode coupled with a triple quadrupole mass spectrometry, API 4000QT, monitoring two transitions for each analyte, one for the quantification and the other for confirmation. The method could be easily applied to the clinical practice thanks to the short run (7 min), the low amount of patient plasma necessary for the analysis (5 mu L) and the fast sample processing based on protein precipitation. The method was therefore fully validated according to FDA and EMA guidelines. The linearity was assessed (R-2 >= 0.998) over the concentration ranges of 50-8000 ng/mL for SORA and REGO, and 30-4000 ng/mL for their metabolites, that appropriately cover the therapeutic plasma concentrations. The presented method also showed adequate results in terms of intra- and inter-day accuracy and precision (CV <= 7.2% and accuracy between 89.4% and 108.8%), recovery (>= 85.5%), sensitivity, analytes stability under various conditions and the absence of the matrix effect. Once the validation was successfully completed, the method was applied to perform the C-min quantification of SORA, REGO and their metabolites in 54 plasma samples collected from patients enrolled in a clinical study ongoing at the National Cancer Institute of Aviano. (C) 2020 Elsevier B.V. All rights reserved.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Therapeutic drug monitoring and LC-MS/MS
    Adaway, Joanne E.
    Keevil, Brian G.
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2012, 883 : 33 - 49
  • [2] Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS
    Allard, Marie
    Khoudour, Nihel
    Rousseau, Benoit
    Joly, Charlotte
    Costentin, Charlotte
    Blanchet, Benoit
    Tournigand, Christophe
    Hulin, Anne
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2017, 142 : 42 - 48
  • [3] LC-MS/MS for immunosuppressant therapeutic drug monitoring
    Sallustio, Benedetta C.
    BIOANALYSIS, 2010, 2 (06) : 1141 - 1153
  • [4] A Simple and Rapid LC-MS/MS Method for Therapeutic Drug Monitoring of Lenalidomide
    Nesetoglu, Neset
    Kaplan, Cem
    Aslan, Serap Saglik
    Unal, Durisehvar Ozer
    PAKISTAN JOURNAL OF ANALYTICAL & ENVIRONMENTAL CHEMISTRY, 2020, 21 (01) : 19 - 26
  • [5] A Novel LC-MS/MS Method for Therapeutic Drug Monitoring of Baricitinib in Plasma of Pediatric Patients
    Cafaro, Alessia
    Baiardi, Giammarco
    Pigliasco, Federica
    Barco, Sebastiano
    Mattioli, Francesca
    Volpi, Stefano
    Caorsi, Roberta
    Gattorno, Marco
    Cangemi, Giuliana
    THERAPEUTIC DRUG MONITORING, 2024, 46 (01) : 67 - 72
  • [6] LC-MS/MS method for the quantification of cortisol of hepatocellular carcinoma
    Zhou, Zijing
    Li, Xiaoshuang
    Yin, Shengjun
    Zhang, Zhiyuan
    Li, Xiaoyue
    Miao, Xiaojie
    Cheng, Haixu
    Lou, Yaqing
    Tu, Pengfei
    Lu, Yingyuan
    Zhang, Guoliang
    BIOMEDICAL CHROMATOGRAPHY, 2024, 38 (04)
  • [7] A simple and sensitive LC-MS/MS method for therapeutic drug monitoring of digoxin in children
    Yang, Zhi-mei
    Qin, Ya-bin
    Zhao, De-yun
    Wang, Lan-tao
    Tian, Ying-ping
    Liu, Jian-fang
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2023, 1221
  • [8] Simple and robust LC-MS/MS analysis method for therapeutic drug monitoring of micafungin
    Boonstra, Jasper M.
    Jongedijk, Erwin M.
    Koster, Remco A.
    Touw, Daan J.
    Alffenaar, Jan-Willem C.
    BIOANALYSIS, 2018, 10 (11) : 877 - 886
  • [9] Evaluation of a straightforward and rapid method for the therapeutic drug monitoring of digitoxin by LC-MS/MS
    Bremer-Streck, Sibylle
    Kiehntopf, Michael
    Ihle, Stefan
    Boeer, Klas
    CLINICAL BIOCHEMISTRY, 2013, 46 (16-17) : 1728 - 1733
  • [10] Innovative LC-MS/MS method for therapeutic drug monitoring of fenfluramine and cannabidiol in the plasma of pediatric patients with epilepsy
    Pigliasco, Federica
    Cafaro, Alessia
    Barco, Sebastiano
    Stella, Manuela
    Mattioli, Francesca
    Riva, Antonella
    Mancardi, Maria Margherita
    Lattanzi, Simona
    Bandettini, Roberto
    Striano, Pasquale
    Cangemi, Giuliana
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2024, 245